RetInSight GA Monitor
The RetInSight GA Monitor for Geographic Atrophy (GA)
AI-based segmentation in clinical practice: Making the invisible visible
Sample of a RetInSight GA Monitor PDF Report
Key features of the RetInSight GA Monitor
- AI-based Segmentation: Advanced AI algorithms enable precise segmentation of GA areas
- Disease Activity Assessment: Measure and visualize disease activity and therapeutic efficacy across all aspects, including
- Precise and Plausible Disease Monitoring: Visualize and track disease progression, allowing for precise and timely interventions
- Regulatory Compliance: The RetInSight GA Monitor is the first and only AI-based software fulfilling all MDR 2017/745 requirements for Class IIa medical devices as Clinical Decision Support Systems (CDSS) for the monitoring of patients with GA
Sample of a RetInSight GA Monitor PDF Report
Why the RetInSight GA Monitor is a game-changer in GA management
The RetInSight GA Monitor has been thoughtfully crafted to address the unique challenges of GA diagnosis and progression tracking:
- Unique photoreceptor visualization: Be at the forefront of GA management with the unique ability to measure photoreceptor degeneration, the primary sign of GA and the essence of vision1
- Identify progression: Distinguish slow vs. fast progressors at first presentation and track the speed of development of RPE and PR integrity loss in each patient and over time, enabling personalized treatment and a realistic assessment of therapeutic benefit3, 4, 5
- Efficient workflow: Integrate GA management seamlessly into your current OCT routine, streamlining workflow and enhancing efficiency with a mouse click
- Quality control: Replace time-consuming and error-prone human image analysis with fast, reproducible, and quantifiable real-time data supporting informed therapeutic decisions
- Patient communication: Foster patient compliance by delivering customized, real-time reports also to patients, ideally reducing the risk of over- and under-treatment and increasing trust with self-explanatory, personalized reports
Empowering GA management through visualization and quantification of PR degeneration and RPE loss on standard OCT images
As a trusted leader in retinal care, RetInSight invites you to explore the GA Monitor and experience the next generation of GA management. Our innovative technology will empower you to make informed treatment decisions based on precise measurements and visualizations of PR and RPE loss, all while remaining committed to preserving your patients’ vision throughout their lifetime.
The RetInSight GA Monitor is the first and only AI-based software fulfilling all MDR 2017/745 requirements for Class IIa medical devices as Clinical Decision Support Systems (CDSS) for the monitoring of patients with GA.
For more information and a demo of the RetInSight GA Monitor, please get in touch with our team. Together, let’s revolutionize the way we manage and treat geographic atrophy.
References
- Julia Mai et al. | Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography–based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy
- Sophie Riedl et al. | The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence – Based OCT Analysis
- Wolf-Dieter Vogl et al. | Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
- Ursula Schmidt-Erfurth et al. | Monitoring der Progression von geografischer Atrophie in der optischen Kohärenztomographie
- Ursula Schmidt-Erfurth et al. | Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT